Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
+1M
-
Total reported value, excl. options
-
$815M
-
Value change
-
+$8.36M
-
Put/Call ratio
-
0.6
-
Number of buys
-
48
-
Number of sells
-
-50
-
Price
-
$8.07
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2018
136 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2018.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
of 210M outstanding shares and own 48.18% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (15.1M shares), JANUS HENDERSON GROUP PLC (12.3M shares), RA CAPITAL MANAGEMENT, LLC (10.7M shares), BlackRock Inc. (8.85M shares), GREAT POINT PARTNERS LLC (7.62M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (6.91M shares), Vanguard Group Inc (5.87M shares), JENNISON ASSOCIATES LLC (3.8M shares), VHCP Management II, LLC (3.25M shares), and VHCP Management III, LLC (3.06M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.